

Fax completed prior authorization request form to 855-247-3677 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. Incomplete forms or forms without the chart notes will be <u>returned</u>

Pharmacy Coverage Guidelines are available at <a href="https://www.mercycareaz.org/providers/pharmacy.html">www.mercycareaz.org/providers/pharmacy.html</a>

## **Xolair**

Pharmacy Prior Authorization Request Form

Do not copy for future use. Forms are updated frequently.

REQUIRED: Office notes, labs, and medical testing relevant to request showing medical justification are required to support diagnosis Member Information

Member Name (first & last):	Date of	Date of Birth:			Gender:				Height:					
				□ Male □ Fer			male							
Member ID:	City:			State:		- 1	Weight:							
Prescribing Provider Information														
Provider Name (first & last):	Specia	Specialty:			NPI#			DEA#						
Office Address:	City:			State:	Zip Code:									
Office Contact:		Office Phone			Office Fax:				_1					
Dispensing Pharmacy Information		1												
Pharmacy Name:		Pharmacy	Phone:		Ph	armacy Fax:								
Requested Medication Information														
What medication(s) has member tried and failed for this diagnosis? Please specify:														
			Diagnosi	is:	ICD-10 Code:									
Are there any contraindications to formulary medications?  If yes, please specify:						1		Yes		No				
Directions for Use:	Strength: Dosage Form:													
		Quantity: Day Du			Duration of Therapy/Use:									
		~~~,.			Burdaen et merapyrese.									
Turn-Around Time for Review														
☐ Standard – (24 hours) ☐ Urgent – waiting 24 hours for a standard decision could seriou or ability to regain maximum function, you can ask for an expect Signature:						•								
Clinical Information														
□ Allergic Asthma														
Has documentation (e.g., chart notes) been submitted confirming diagnosis of moderate to severe persistent allergic asthma?						Yes		1 [	No					
Has documentation (e.g., chart notes, lab values) been submitted confirming a positive skin test or in vitro reactivity to a perennial aeroallergen?						Yes	Г	1	No					
Is the member 12 years of age or older with documentation of a pre-treatment serum immunoglobulin (lg)E level between 30 to 700 IU/mL?						Yes	Г	1 [	No					
Member is 6 years to less than 12 years of age with documentation of a pre-treatment serum immunoglobulin (Ig)E level between 30 to 1300 IU/mL?							Yes			No				
Use of High-dose inhaled corticosteroid (ICS) (e.g., >500 mcg fluticasone propionate equivalent/day)	Use of asthma controller medication (e.g., leukotriene receptor antagonist [e.g., montelukast], LABA [e.g., salmeterol], tiotropium)  Use of one maximally dosed COMBO ICS/LABA product (e.g., Advair [fluticas propionate-salmeterol], Symbicort [budesonide-formoterol], Breo Ellipta [fluticasone-vilanterol])													

Effective: 6/01/2024 C23396-A

**Renewal Requests ONLY** 

Was documentation (e.g., chart notes) submitted confirming a positive clinical response to therapy (e.g., reduction in exacerbations, improvement in FEV1, decreased use of rescue medications)?						□ Y€	es		No			
Are there paid claims or documentation (e.g., chart notes) submitted confirming patient continues to be treated with an ICS (e.g., fluticasone, budesonide) WITH OR WITHOUT additional asthma controller medication (e.g., leukotriene receptor antagonist [e.g., montelukast], LABA [e.g., salmeterol], tiotropium)?						□ Ye	es		No			
Is there is a contraindication or intolera					.g., cannotore	ij, dodropiamij.	□ Ye	es		No		
☐ Chronic Spontaneous Urticaria												
Was documentation (e.g., chart notes), confirming diagnosis of chronic spontaneous urticaria submitted?						□ Ye	es		No			
Does the member have persistent symptoms (itching and hives) for at least 4 consecutive weeks despite titrating to an optimal dose with a second generation H1 antihistamine (e.g., cetirizine, fexofenadine), unless there is a C/I or intolerance to H1 antihistamines?						□ Ye			No			
Does the member have paid claims or documentation has been submitted (e.g., chart notes) confirming concurrent use with an H1 antihistamine, unless there is a C/I or intolerance to H1 antihistamines?							□ Ye	es		No		
Member have TWO of the following, with paid claims				Doxepin		histamine 🛭	H2-ant		ine (fa	amoti	idine,	
or submission of documentation (e.g., chart notes)			hydroxyzine									
□ Renewal Requests ONLY												
Has the member's disease status been RE-EVALUATED since the last authorization to confirm the patient's condition warrants continued treatment?												
Submission of documentation (e.g., ch. confirming patient has experienced at the following:		f		Reduction in ito from baseline	uction in baseline	n the number of hives ne						
☐ Chronic Rhinosinusitis with Nas	sal Polyps											
				Mucopurulent o	lischarge	☐ Nasa	al obstru	ction ar	nd cor	ngest	ion	
Submission of documentation (e.g., chart notes) confirming TWO or more of the following symptoms for ≥12 weeks:				Decreased or absent sense of smell □ Facial pressure or pain								
Submission of documentation confirming ONE of the following:				paranasal sinus exam or CT								
			☐ Evidence of purulence coming from paranasal sinuses OR ostiomeatal complex									
Submission of documentation confirming the following:			☐ Required prior sino-nasal surgery OR systemic corticosteroids in the previous 2 years									
			□ Nasal saline irrigations									
Member has been unable to obtain symptom relief after ALL the following agents/classes of agents:			☐ Intranasal corticosteroids (e.g., fluticasone, mometasone, triamcinolone, etc.)									
			☐ Antileukotriene agents (e.g., montelukast, zafirlukast, zileuton)									
Is member currently on Xolair therapy?	□ Yes		No	Will member re COMBO w/intra		s ADD ON thera s?	py in		es/		No	
				Is member rece biologic [e.g., D		COMBO with a	nother		es/		No	
☐ Renewal Requests ONLY												
Was documentation (chart notes, lab values) submitted confirming a positive clinical response to Xolair therapy?								⁄es		No		
Will member receive Xolair as ADD ON therapy in COMBO w/intranasal steroids?							_ \	⁄es		No		
Is member receiving Xolair in COMBO with another biologic [e.g., Dupixent, Nucala]?							_ \	⁄es		No		
□ IgE Medicated Food Allergy												
Documentation (chart notes, lab values) submitted, confirming diagnosis of IgE Mediated Food Allergy as evidenced by ONE of the following:		Positive skin prick test (defined as greater than or equal to 4mm wheal greater than saline control) to food										
		□ Positive food specific IgE (greater than or equal to 6kUA/L)										
, ,			☐ Positive oral food challenge, defined as experiencing dose-limiting symptoms at a single dose of less than or equal to 300mg of food protein									
Does member have clinical history of IgE Mediated Food Allergy OR documentation (chart notes, lab values) was submitted confirming a HX of severe allergic response, including anaphylaxis, following exposure to one or more foods?							No					
Xolair is used in conjunction with ☐ Documentation was submitted confirming ☐												

Effective: 6/01/2024 C23396-A

□ Renewal Requests ONLY											
Was documentation (chart notes, lab values) submitted confirming a positive response to therapy (e.g., reduction		Yes		No							
of type 1 allergic reactions, including anaphylaxis, following accidental exposure to one or more foods)?  Will Xolair be used in conjunction with food allergen avoidance?		Yes		No							
· · · · · · · · · · · · · · · · · · ·											
Was documentation (chart notes, lab values) submitted confirming that dosing will continue to be based on body weight AND pretreatment total IgE serum levels?		Yes		No							
Additional information the prescribing provider feels is important to this review. Please specify below or submit medical records.											
Signature affirms that information given on this form is true and accurate and reflects office notes.											
Prescribing Provider's Signature: Dat	ə:										

## Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required Standard turnaround time is 24 hours. You can call 800-564-5465 to check the status of a request.

Effective: 6/01/2024 C23396-A